Displaying drugs 326 - 350 of 406 in total
| Name | Weight | Structure | Desription | Categories |
|---|---|---|---|---|
| Inotuzumab ozogamicin | Not Available |  | An antibody-drug conjugate used to treat B-cell precursor acute lymphoblastic leukemia (ALL). | Antibodies, Monoclonal / CD22 (Clusters of Differentiation 22) inhibitors |
| Trastuzumab emtansine | Not Available | | An antineoplastic agent and antibody-drug conjugate used to treat HER2-overexpressing breast cancer. | Antibodies, Monoclonal / HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors |
| Sulesomab | Not Annotated | | Market product is Tc99m-labeled murine antibody fragment for nuclear imaging of activated granulocytes. | Technetium (99Mtc) Compounds |
| Besilesomab | Not Available |  | A monoclonal antibody bound to technetium-99 used to find infection and inflammation in patients with suspected osteomyelitis. | Radiopharmaceuticals |
| Erenumab | C6472H9964N1728O2018S50 | | A calcitonin-gene related peptide antagonist used to prevent migraines. | Calcitonin Gene-Related Peptide (CGRP) Antagonists / Calcitonin Gene-Related Peptide Receptor Antagonists |
| Fanolesomab | Not Annotated | | An anti-SSEA-1 monoclonal antibody used for imaging of the appendix and to diagnose appendicitis. | Lewis X Antigen |
| Trastuzumab deruxtecan | Not Available | | An antibody used to treat certain types of unresectable or metastatic HER2 positive breast cancer. | HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors |
| Sacituzumab govitecan | Not Available | | Sacituzumab govitecan targets TROP-2-expressing cancer cells through a humanized antibody (RS7) before subsequently becoming internalized and releasing the topoisomerase I inhibitor SN-38 to induce DNA damage-mediated apoptosis. | Alkaloids / Amino Acids, Peptides, and Proteins / Antibodies / Antibodies, Monoclonal / Antibodies, Monoclonal, Humanized / Antibody-drug Conjugates / Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / Blood Proteins / Cancer immunotherapy / Globulins / Immunoglobulins / Immunologic Factors / Immunoproteins / Immunotherapy / MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES / Noxae / Proteins / Serum Globulins / Topoisomerase Inhibitors / Toxic Actions / Trop-2-Directed Monoclonal Antibodies / UGT1A1 Substrates |
| Belantamab mafodotin | Not Available | | An anti B-cell maturation antigen antibody conjugated to a microtubule inhibitor to treat relapsed or refractory multiple myeloma. | Amino Acids, Peptides, and Proteins / Antibodies / Antibodies, Monoclonal / Antibodies, Monoclonal, Humanized / Antibody-drug Conjugates / Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / Blood Proteins / BSEP/ABCB11 Substrates / Cancer immunotherapy / Globulins / Immunoglobulins / Immunoproteins / Immunotherapy / MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES / OATP1B1/SLCO1B1 Substrates / OATP1B3 substrates / P-glycoprotein substrates / Proteins / Serum Globulins / Tubulin Inhibiting Agent |
| Imdevimab | Not Available | | Part of an investigational recombinant monoclonal antibody cocktail used to treat mild to moderate COVID-19. | Antiviral monoclonal antibodies |
| Casirivimab | Not Available | | Part of an investigational recombinant monoclonal antibody cocktail used to treat mild to moderate COVID-19. | Antiviral monoclonal antibodies |
| Regdanvimab | Not Available | | A monoclonal antibody targeted against the SARS-CoV-2 spike protein used to treat patients with COVID-19 who are at risk of progressing to severe COVID-19. | Antiviral monoclonal antibodies |
| Pucotenlimab | Not Annotated | | Pucotenlimab is a recombinant humanized anti-PD-1 monoclonal antibody. It received its first global approval in China in July 2022 for the treatment of solid tumours. It is being investigated in... | Not Annotated |
| Tislelizumab | Not Available | | An IgG4 variant monoclonal antibody against PD-1 indicated for the treatment of unresectable, locally advanced or metastatic esophageal squamous cell carcinoma | PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors |
| Anthrax immune globulin human | Not Available | | An immunizing agent used for the treatment of inhalational anthrax in adult and pediatric patients in combination with antibacterial agents. | Amino Acids, Peptides, and Proteins / Blood Proteins / Human Immunoglobulin / Immunoglobulins / Proteins / Serum / Serum Globulins / Vaccines |
| Antithymocyte immunoglobulin (rabbit) | Not Annotated |  | A purified form of rabbit anti-thymocyte antibodies used for immunosuppression in patients receiving kidney transplants. | Selective Immunosuppressants |
| Hepatitis B immune globulin | Not Available | | An injection of immunoglobulin G (IgG) antibodies to prevent the development of chronic Hepatitis B infection. | Specific Immunoglobulins |
| Rabies immune globulin, human | Not Available | | A solution of antibodies used to prevent rabies after an exposure. | Human Rabies Immune Globulins / Serum / Vaccines |
| Human Rho(D) immune globulin | Not Available | | A solution of antibodies used to prevent isoimmunization of Rho(D) negative patients exposed to Rho(D) positive blood in pregnancy or transfusion. | Specific Immunoglobulins |
| Human varicella-zoster immune globulin | Not Available | | A solution of antibodies used for post exposure prophylaxis of varicella infections in high risk populations, as well as to reduce the severity of infections. | Immunization, Passive |
| Tetanus immune globulin, human | Not Available |  | A solution of antibodies used to prevent tetanus after an injury. | Specific Immunoglobulins |
| Equine Botulinum Neurotoxin B Immune FAB2 | Not Available | | A mixture of antibodies used to treat documented or suspected botulinum toxin exposure. | Not Available |
| Equine Botulinum Neurotoxin A Immune FAB2 | Not Available | | A mixture of antibodies used to treat documented or suspected botulinum toxin exposure. | Not Available |
| Equine Botulinum Neurotoxin C Immune FAB2 | Not Available | | A mixture of antibodies used to treat documented or suspected botulinum toxin exposure. | Not Available |
| Equine Botulinum Neurotoxin D Immune FAB2 | Not Available | | A mixture of antibodies used to treat documented or suspected botulinum toxin exposure. | Not Available |
Displaying drugs 326 - 350 of 406 in total